ArticleJCI insight2018
Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.
Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 39 citations in OpenAlex.
- Monocytes in pneumonia: Functional plasticity and innate memory (Review).International journal of molecular medicine · 2026Review
- Inhaled pattern recognition receptor agonists promote inducible epithelial resistance against murine betacoronavirus disease.American journal of physiology. Lung cellular and molecular physiology · 2026Article
- Respiratory viral coinfections: interactions, mechanisms and clinical implications.Nature reviews. Microbiology · 2025Review
- Experimental Models to Investigate Viral and Cellular Dynamics in Respiratory Viral Co-Infections.Microorganisms · 2025Review
- Article
- Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.Journal of virology · 2024Article
- Nasal virus infection induces asthma exacerbation through B-cell-dependent recruitment of inflammatory monocytes.International forum of allergy & rhinology · 2024Article
- Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.Nature communications · 2024Article
- A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response.Vaccines · 2024Article
- Defining Parameters That Modulate Susceptibility and Protection to Respiratory Murine Coronavirus MHV1 Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Article
- Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.The Libyan journal of medicine · 2023Article
- Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.Research square · 2023Article
- Fragility and contagiousness of the total laryngectomy patient in the COVID-19 pandemic.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022Article
- Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict β-coronaviral infection and replication.Virology · 2022Article
- Priming With Rhinovirus Protects Mice Against a Lethal Pulmonary Coronavirus Infection.Frontiers in immunology · 2022Article
- Mucormycosis in COVID-19 pandemic: Risk factors and linkages.Current research in microbial sciences · 2021Article
- Interleukin-4 protects mice against lethal influenza and Streptococcus pneumoniae co-infected pneumonia.Clinical and experimental immunology · 2021Article
- Risk for COVID-19 infection in patients with tobacco smoke-associated cancers of the upper and lower airway.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.